Paula Alves, CEO
Paula Alves is the CEO of iBET, the Head of the Animal Cell Technology Unit at iBET and Professor at NOVA University of Lisbon (ITQB and FCT). She received her Ph.D. at Biochemical Engineering from the NOVA University of Lisbon, in 2001, and her B.S in Biochemistry from the Sciences Faculty of the University of Lisbon, in 1991. Working in Animal Cell Technology since 1990, her PhD contributed to the establishment of 3D in vitro models of Brain Cells for metabolic trafficking studies. She did part of her PhD studies at the NMR Center-Sintef, Trondheim Hospital, Norway and at the NMR Laboratory of the Chemistry Department of Bremen University. Professor Alves' research integrates cell metabolism understanding with biochemical engineering for the improvement of bioprocesses efficiency also focusing on the development of new tools and technologies for pre-clinical research. Professor Paula Alves is currently the Chairperson of the ESACT (European Society for Animal Cell Technology) and Member of the IMI (Innovative Medicines Initiative) Scientific Council and of EURL-ECVAM (EU Reference Laboratory for Alternatives to Animal Testing). She was a member of the Advisory Board of Horizon 2020 Societal Challenge 1 - European Commission, between 2013 and 2018. She has published over 230 papers, 32 book chapters and supervised 35 PhD students, 18 post-docs and several master theses. In 2009 she received the Scientific Merit Award from NOVA University of Lisbon and in 2017 she was recognized as one of the 100 Top Portuguese Women in Science.
Manuel Carrondo, Vice-President and founder of iBET
Manuel Carrondo is Full Professor of Chemical and Biochemical Engineering at the Faculty of Sciences and Technology at NOVA University of Lisbon. He has extensive management experience in the biotechnology sector and heads iBET’s Business Development. His key areas of interest include (i) Animal Cell Technology and its application for human and animal health, (ii) therapeutic and diagnostic recombinant proteins, including fusion proteins, (iii) virus-like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-) as deliverables for gene therapy, (iv) cell therapies and stem cells and (v) cGMP pilot plant scale-up and production development of biopharmaceuticals. Professor Manuel Carrondo is Advisory Board Member of CEVEC Pharmaceuticals, PBS Biotech, CNIC (Spanish National Center for Cardiovascular Research Carlos III), Masthercells (Manufacturing Synergies for Therapeutic Cells), Alloksys Life Sciences BV, IBMT (Fraunhofer Institute for Biomedical Engineering), and GenIbet Biopharmaceuticals. He is also the Portuguese representative to the Working Party on Biotechnology, Nanotechnology and Converging Technologies of OECD (The Organisation for Economic Co-operation and Development). Manuel Carrondo has published over 230 papers and supervised 35 PhD students.